Ngā hua rapu - Gregory K. Pennock
- E whakaatu ana i te 1 - 4 hua o te 4
-
1
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment mā Gregory K. Pennock, Laura Q.M. Chow
I whakaputaina 2015Revisão -
2
Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies mā Mayer Fishman, John A. Thompson, Gregory K. Pennock, René González, Luz M. Diez, Adil Daud, Jeffery S. Weber, Bee Y. Huang, Shamay Tang, Peter R. Rhode, Hing C. Wong
I whakaputaina 2011Artigo -
3
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer mā Jean Bourhis, Alexander Stein, Jan Paul de Boer, Marc Van den Eynde, Kathryn A. Gold, Sebastian Stintzing, Jürgen C. Becker, Michael Moran, Andreas Schröeder, Gregory K. Pennock, Satu Salmio, Regina Esser, Fortunato Ciardiello
I whakaputaina 2021Revisão -
4
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis mā Andrea B. Apolo, John Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael S. Gordon, Raid Aljumaily, Theodore Stewart Gourdin, Luc Dirix, Keunwook Lee, Matthew H. Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Juliane Manitz, Gregory K. Pennock, Mary Ruisi, James L. Gulley, Manish R. Patel
I whakaputaina 2020Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Cancer
Internal medicine
Medicine
Immunology
Immunotherapy
Oncology
Avelumab
Chemotherapy
Immune system
Antibody
Antibody-dependent cell-mediated cytotoxicity
Bladder cancer
Cancer immunotherapy
Cancer research
Carcinoma
Cetuximab
Clinical trial
Confidence interval
Epidermal growth factor receptor
Gastroenterology
Hazard ratio
Immune checkpoint
Immunogenic cell death
Interleukin 2
Merkel cell carcinoma
Metastatic Urothelial Carcinoma
Modalities
Monoclonal antibody
Neutropenia
Nivolumab